Our current methods are based on over twenty years of academic research and provide an unrivalled sensitivity in detecting irreversible covalent bindings. We continuously develop our methods to expand the range of practical applications and offer tailor made solutions for individual customers.
We have a longstanding collaboration with Karolinska Institute where our product series Tailor Dose™ is used in ongoing clinical trials to further explore the potential of therapeutic drug monitoring and individual dose adjustment.
The study was conducted with the main objective to evaluate biomarkers as a tool for individual dose adjustments. We wanted to look at correlations between biomarkers and toxicity. The secondary aim was to look at correlations with single nucleotide polymorphism genotype data to evaluate whether patients in risk of under or overdose can be predicted via genetic markers. TailorDose was used as a method for determination of in vivo dose of the active components in cytostatic treatment in women with breast cancer.
Clinical samples were gathered between 2012 and 2014 resulting in a clinical cohort of 152 breast cancer patients treated with cyclophospamid and we acquired adduct data from a total of 471 dose cycles. The results are promising and we found a strong correlation between Age and Dose biomarker, indicating that older patients recieves higher in vivo doses of active PAM. Further results are statistically evaluated and a manuscript under way.
Ongoing study at Karolinska Institutet furthering the studies on therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer. The study encompasses female breast cancer patients receiving FEC or EC treatment (epirubicin and cyclophosphamide) with or without subsequent docetaxel or paclitaxel therapy, and patients receiving neo-adjuvant or adjuvant TAC (docetaxel, doxorubicin and cyclophosphamide) will be monitored with a novel strategy consisting of:
TailorDose®, a patented technology which enables exposure measurements of PAM, formed from cyclophosphamide, by analyzing the level of a specific biomarker.
A model based therapeutic drug monitoring approach to measure exposures for epirubicin, doxorubicin, docetaxel, and paclitaxel.